A randomized control study for evaluating the efficacy of individualized homoeopathic medicine as an adjuvant therapy in mild to moderate cases of COVID-19

Understanding the efficacy of indicated homoeopathic medicine as an adjuvant to standard treatment in improving the subjective and objective parameters in patients with mild to moderate confirmed cases of COVID-19. Study design: A prospective randomized control trial conducted at Deenanath Mangeshkar Hospital, Erandwane, Pune, wherein Group A received standard treatment along with indicated homoeopathic medicine (experimental group) and Group B received the standard treatment and placebo (control group). Sample size: Fifty confirmed COVID positive, randomly selected patients in Groups A and B. The indicated homoeopathic medicine as an adjuvant reduced subjective distress in a statistically significant proportion. It also reduced oxygen requirement, shortened hospital stay, promoted early recovery, and reduced worsening of the patients and shifting into the intensive care unit (ICU). By day 4 of treatment, subjective symptoms in 56% of patients in the experimental group were completely resolved, compared to 15% in the control group. The oxygen requirement on day 4 reduced by 46.2% in the experimental group, remaining unchanged in the control group. None of the patients in the experimental group needed shifting to the ICU compared to 16.7% in the control group. The average hospital stay was 6 days in the experimental group, compared to 9 days in the control group. Homoeopathic medicines played a significant role in helping to relieve the subjective and objective parameters of COVID-19.